Argininosuccinic Aciduria Market to Register Sustainable Growth During the Forecast Period (2022-32) – DelveInsight | Key Companies – Evox Therapeutics, Takeda, Ace Therapeutics, Hyperion Therapeutics

Argininosuccinic Aciduria Market to Register Sustainable Growth During the Forecast Period (2022-32) - DelveInsight | Key Companies - Evox Therapeutics, Takeda, Ace Therapeutics, Hyperion Therapeutics
Delveinsight Business Research LLP
As per DelveInsight, the Argininosuccinic Aciduria market dynamics are anticipated to transform immensely in the coming years owing to the rise in the number of Incident cases of Argininosuccinic Aciduria patients in 7MM, the improvement in the diagnosis methodologies, increased R&D activities, and incremental healthcare spending across the world.

DelveInsight’s “Argininosuccinic Aciduria Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Argininosuccinic Aciduria market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Argininosuccinic Aciduria market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Argininosuccinic Aciduria Market

Argininosuccinic Aciduria: An Overview

The urea cycle disorders are a group of rare disorders affecting the urea cycle, a series of biochemical processes in which nitrogen is converted into urea and removed from the body through the urine. Nitrogen is a waste product of protein metabolism. Failure to break down nitrogen results in the abnormal accumulation of nitrogen, in the form of ammonia, in the blood. Argininosuccinic aciduria (ASA) is an inherited disorder that causes ammonia to accumulate in the blood. Ammonia, which is formed when proteins are broken down in the body, is toxic if the levels become too high. The nervous system is especially sensitive to the effects of excess ammonia.

Occasionally, individuals may inherit a mild form of the disorder. These individuals can have an accumulation of ammonia in the bloodstream only during periods of illness or other stress or mild intellectual disability or learning disabilities with no evidence of elevated ammonia levels.

Argininosuccinic Aciduria Market Key Facts

  • According to NORD, Argininosuccinic aciduria is a rare disorder that affects fewer than a thousand people in the United States. It is estimated to affect anywhere between approximately one in 70,000 to 1 in 218,000 live births. Most cases of this condition are detected shortly after birth by newborn screening.

  • As per the European Medicines Agency, argininosuccinic aciduria affected approximately 0.07 in 10,000 people in the European Union (EU). This was equivalent to a total of around 4,000 people and is below the threshold for orphan designation, which is 5 people in 10,000.

Argininosuccinic Aciduria Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Argininosuccinic Aciduria market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Argininosuccinic Aciduria market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Argininosuccinic Aciduria Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Argininosuccinic Aciduria Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Argininosuccinic Aciduria market or expected to be launched during the study period. The analysis covers the Argininosuccinic Aciduria market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Argininosuccinic Aciduria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Argininosuccinic Aciduria Market Will Evolve by 2032 @

Some of the key companies in the Argininosuccinic Aciduria (ASA) market include:

  • Evox Therapeutics 

  • Takeda

  • Ace Therapeutics

  • Hyperion Therapeutics

And many others.

Argininosuccinic Aciduria Therapies covered in the report include:

  • ACER-001

  • Ravicti

And many others. 

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Argininosuccinic Aciduria Competitive Intelligence Analysis

4. Argininosuccinic Aciduria Market Overview at a Glance

5. Argininosuccinic Aciduria Disease Background and Overview

6. Argininosuccinic Aciduria Patient Journey

7. Argininosuccinic Aciduria Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Argininosuccinic Aciduria Treatment Algorithm, Current Treatment, and Medical Practices

9. Argininosuccinic Aciduria Unmet Needs

10. Key Endpoints of Argininosuccinic Aciduria Treatment

11. Argininosuccinic Aciduria Marketed Products

12. Argininosuccinic Aciduria Emerging Drugs and Latest Therapeutic Advances

13. Argininosuccinic Aciduria Seven Major Market Analysis

14. Attribute Analysis

15. Argininosuccinic Aciduria Market Outlook (In US, EU5, and Japan)

16. Argininosuccinic Aciduria Access and Reimbursement Overview

17. KOL Views on the Argininosuccinic Aciduria Market

18. Argininosuccinic Aciduria Market Drivers

19. Argininosuccinic Aciduria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

Other Trending Healthcare Reports By DelveInsight

Argininosuccinic Aciduria Pipeline Insight

Argininosuccinic Aciduria – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ drugs in the Argininosuccinic Aciduria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States